OncoMatch/Clinical Trials/NCT04702581
A Randomized Trial of Delayed Radiotherapy in Patients Low-grade Oligodendrogliomas Requiring a Treatment Other Than Surgery
Is NCT04702581 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies multiple treatments including PCV chemotherapy and Radiotherapy and PCV chemotherapy for oligodendroglioma.
Treatment: PCV chemotherapy · Radiotherapy and PCV chemotherapy — Because of their prolonged survival, patients with 1p/19q-codeleted low-grade oligodendrogliomas treated with RT + PCV are at risk of neurocognitive deterioration. We make the hypothesis that withholding radiotherapy until tumor progression could reduce the risk of neurocognitive deterioration without impairing overall survival.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Glioblastoma
Biomarker criteria
Required: IDH1 mutation
IDH-mutant (IDH1 or IDH2) according to local diagnosis
Required: IDH2 mutation
IDH-mutant (IDH1 or IDH2) according to local diagnosis
Required: 1P deletion
Tumor is co-deleted for 1p and 19q
Required: 19Q deletion
Tumor is co-deleted for 1p and 19q
Disease stage
Grade: low-grade (WHO 2016)
Histological confirmation of low-grade oligodendroglioma by central pathological review according to WHO 2016 classification
Prior therapy
Cannot have received: radiation therapy
Received any prior radiation therapy or chemotherapy for any CNS neoplasm.
Cannot have received: chemotherapy
Received any prior radiation therapy or chemotherapy for any CNS neoplasm.
Lab requirements
Blood counts
anc ≥1500 /mm3; platelet count ≥100,000 / mm3; hemoglobin > 9.0 g/dl
Liver function
total bilirubin ≤ 1.5 x uln; sgot (ast) ≤ 3 x uln
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT04702581 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Does this trial require IDH1?
Yes, IDH1 mutation is a required biomarker for enrollment.
Does this trial require IDH2?
Yes, IDH2 mutation is a required biomarker for enrollment.
Does this trial require 1P?
Yes, 1P deletion is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages